Menarini
Manufacturing · Italy · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Via Sette Santi 1, Florence, Tuscany, 50...Website
www.menarini.itRevenue
$31.5 MillionIndustry
About Menarini
Is Menarini your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Menarini has new funding data
Menarini, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Menarini
Check out if Menarini is spiking on competitors!
Click to see if Menarini had a recent Job posting/layoffs
Earning: See what the market has to say on Menarini recently announced quarterly report
Check if Menarini has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Menarini launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Menarini is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Menarini is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Menarini.
Menarini Tech Stack
A closer look at the technologies used by Menarini
Menarini News & Media
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia
FLORENCE, Italy, Nov. 4, 2021 /PRNewswire/ -- The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available,...Menarini Announces New SEL24/MEN1703 Clinical Data from DIAMOND-01 Trial
Results Confirmed Manageable Safety Profile of SEL24/MEN1703 and Showed Preliminary Efficacy in Relapsed/Refractory Acute Myeloid Leukemia Data to be Presented at ASCO and EHA Virtual Meetings 2021 POMEZIA, Italy, June 1, 2021 /PRNewswire/ -- The Menarini Group announced today that...Menarini Announces New SEL24/MEN1703 Clinical Data from DIAMOND-01 Trial
/PRNewswire/ -- The Menarini Group announced today that additional data have been generated on SEL24/MEN1703, a first-in-class, orally available, dual PIM/FLT3...Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region
Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Menarini
Menarini Italia, established in Naples in 1886 and headquartered in Florence, focuses on high-quality pharmaceuticals and consumer healthcare products. The company offers a wide range of therapeutic areas including cardiology, gynecology, and dermatology, aiming to improve the lives of millions. Menarini is committed to innovation and responsibilit... Read More